Ipilimumab vs Raltegravir
Ipilimumab vs Raltegravir: Overview
This comparison examines the pharmacological differences between Ipilimumab and Raltegravir.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Raltegravir — Small molecule.